Our data demonstrate that mortalin is necessary for proliferation and survival of these tumor cells and that Mito-CP effectively suppresses these cells with IC50 higher than FDA-approved kinase inhibitors, PLX4032, vandetanib, or cabozantinib. This evidence concerns the gene HSPA9 and neoplasm.